A Tailored Exercise Oncology Program for Neuro-Oncology Patients

Cancer Clinical Trial

— ACE-Neuro  

Official title:

ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04831190
• Other study ID #: HREBA.CC-20-0322
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 15, 2021
• Est. completion date: April 15, 2024

Study information

• Verified date: January 2023
• Source: University of Calgary
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Exercise, or physical activity, is beneficial for all cancer survivors. Despite this knowledge, there is generally a gap between the evidence and practice. And this gap is widened with (a) underserved tumour groups in exercise oncology, such as neuro-oncology patients, or (b) underutilized timelines across the cancer treatment phases to deliver exercise oncology education or programming. Thus, our current work is building a hybrid implementation effectiveness study into the clinical care pathway across Alberta in neuro-oncology - ACE-Neuro.

Objectives: The purpose of this study is to assess the impact of an online, tailored exercise oncology program for neuro-oncology patients using a participant-oriented research (POR) approach as well as both quantitative and qualitative research methods. Specifically, the primary outcome of this study is to determine the feasibility of recruitment, referral, triage, adherence, and adverse events. The secondary outcome is to examine the preliminary effectiveness of the neuro-oncology exercise program on patient-reported outcomes and physical function.

Methods: Neuro-oncology patients >18 years and able to consent in English will be referred to a study-based Rehabilitation Triage Clinic, where a Physician-Researcher will assess patients on their overall health and functional status, and next triage them to either ACE-Neuro, rehabilitation oncology, or cancer physiatry. Once referred to ACE-Neuro, participants will partake in a 12-week online exercise program, delivered by a Clinical Exercise Physiologist. Participants will complete online assessments of physical function, patient-reported outcomes, and objective physical activity at baseline (pre-program), 12-weeks (post-program completion), 6-months, and 12-months. The exercise program includes weekly one-on-one online exercise delivery, health coaching to support behaviour change, and access to an online group exercise session. Participants will also be invited to a post-program qualitative interview to get perspectives on their experiences participating in ACE-Neuro.

Relevance: By working directly with patients, healthcare providers, and community partners, this implementation project will develop a framework that streamlines patient triage, and provides a tailored online exercise program for neuro-oncology patients, thereby advancing exercise oncology research and clinical practice.

Description:

BACKGROUND & RATIONALE

Exercise, or physical activity, is beneficial for all cancer survivors. Despite this knowledge, there is generally a gap between the evidence and practice. And this gap is widened with (a) underserved tumour groups in exercise oncology, such as neuro-oncology patients, or (b) underutilized timelines across the cancer treatment phases to deliver exercise oncology education or programming.

Within Alberta (AB), the investigators have been able to very successfully implement the Alberta Cancer Exercise (ACE) program to start to address the gap between research and practice. As a hybrid implementation effectiveness study, ACE is building a model for exercise oncology delivery within standard cancer care. With over 2500 participants across AB, the investigators have substantial evidence supporting the feasibility of ACE, as well as the potential benefits. Despite these successes, ACE remains primarily represented by participants from breast, prostate, and colorectal tumour groups. This represents a lack of connection between smaller and more high risk tumour groups within referral pathways for the ACE program, both at TBCC and CCI, but also within the regional community cancer clinics (Grande Prairie, Red Deer, Medicine Hat, Lethbridge).

RESEARCH QUESTION & OBJECTIVES

The purpose of this feasibility-implementation study is to build exercise into the clinical care pathway in neuro-oncology clinics at the two major cancer centres in AB, where all neuro-oncology patients provincially are treated (Tom Baker Cancer Centre, TBCC; and the Cross Cancer Institute, CCI). Specifically, the objectives of the proposed work are: (1) to tailor the ACE exercise program for all neuro- oncology patients, to ACE-Neuro; this includes considering additional tailoring to address needs earlier in the care pathway, from diagnosis through treatment (i.e., prehabilitation phases) and into longer term survivorship (wellness cancer survivorship care plans), (2) to provide models of delivery of exercise oncology programs to enhance access (i.e., remote delivery, home support, individual vs group), and (3) to build this systematically within the neuro-oncology clinics at the TBCC and CCI, to ensure that all patients diagnosed with brain tumours can access wellness during their cancer care journey. The investigators hypothesize that there will be improvements in patients' physical and psychosocial well-being (individual level outcomes), as well as a more integrated workflow in the clinical cancer care setting that includes exercise as part of standard clinical practice (systems level outcome). Specifically, the primary outcome of this study is to determine the feasibility of recruitment, referral, triage, adherence, and adverse events. The secondary outcome is to examine the preliminary effectiveness of the neuro-oncology exercise program on patient-reported outcomes and physical function.

METHODS

Using the successful implementation model developed in ACE, the proposed work will build a neuro-oncology cohort within a mixed methods study design. There will be multiple phases to the implementation of ACE-Neuro, including:

1. Building awareness within the clinical teams, identifying site champions, and providing educational and referral resources specific to neuro-oncology and exercise;

2. Working with neuro-oncology patients and families to develop the unique aspects of exercise programming (from "move more" programs to "exercise") to address identified needs. This co-creation process will also include the cancer physiatry team (Dr. George Francis, Dr. Lauren Capozzi) and the clinical neuro-oncology teams (Dr. Gloria Roldan Urgoiti at TBCC and Dr. Jay Easaw at CCI) to address medical clinical needs that can be addressed within the ACE-Neuro program, and clinical workflow logistics with physiatry and physiotherapy to address specific treatment-related side effects (such as limb weakness, balance, or cognitive function);

3. implementation of the ACE-Neuro tailored program, including referral, screening, assessments, intervention delivery, and follow-ups. Details of the ACE-Neuro procedures are detailed below.

REFERRAL AND RECRUITMENT

Because the main outcome of this study is feasibility, and the ultimate goal is to build ACE-Neuro into standard neuro-oncology care, no a priori sample size has been calculated. Based on current clinical numbers, and previous work done with neuro-oncology patients at CCI, the investigators anticipate approximately 25-30 eligible patients per year, per site. Our aim is to referral of all eligible neuro-oncology patients from TBCC. For recruitment, patients can:

1. self-refer (i.e. patient contacts the study team from a poster or brochure received in clinic, through word of mouth);

OR study team can refer:

2. clinical team sends referral to rehab oncology via Putting Patients First Questionnaire (via ARIA).

The clinical team, based on their judgment, may not refer patients they deem to be ineligible. This may include for the following reasons:

1. Patient is not interested when exercise idea is brought up.

2. Health care provider deems patient clinically ineligible, due to disease progression, end-of-life care, or other health factor

3. Patient does not speak English

4. Other

As a feasibility study, reasons for non-referral will be tracked, with no identifying patient information, across the recruitment period. After consenting to the study, all patients will undergo a two-part screening procedure prior to beginning the exercise program:

1. Patients will complete health and medical history screening using the Health History Questionnaire, Identifying Information Questionnaire, and the Physical Activity Readiness Questionnaire; PAR-Q.

2. Patients will attend a Neuro Oncology Rehabilitation Triage Clinic, led by a Resident Physician (Dr. Lauren Capozzi; supervised by Dr. George Francis) and the ACE-Neuro Study Coordinator (Julia Daun). During this 30-minute appointment, patients will complete the Short Physical Performance Battery screening test6, and a full neurological exam, including Karnofsky performance and Eastern Cooperative Oncology Group (ECOG) scores. This appointment will assess the patients' readiness for participating in ACE-Neuro.

As part of this study, the investigators will be tracking the referral pathway, and which method of referral is most feasible as part of standard clinical workflow.

ASSESSMENTS

1. Patient-Reported Outcomes (PROs) - will include symptom burden (Edmonton Symptom Assessment Scale-Revised; ESAS-r), PA levels (Godin Leisure Time Exercise Questionnaire-Modified; GLTEQ), quality of life (Functional Assessment of Cancer Therapy-Brain; FACT-Br), cognitive function (Functional Assessment of Cancer Therapy-Cognitive Scale; FACT-Cog), and fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue; FACIT-F).

2. Functional Fitness Assessments - will follow the set protocols within ACE (HREBA-CC-16- 0905_MOD12), and are designed to be able to be completed in-person or via remote delivery (online assessment). All fitness assessments will be completed by a Clinical Exercise Physiologist and will include the assessment of lower body strength and endurance (30-second sit-to-stand), static balance (single leg stance), flexibility (sit-and-reach and active shoulder flexion), and cardiorespiratory fitness (2-minute step test or 6MWT).

3. Objective Physical Activity - will be measured via the use of a wrist-worn activity tracker (WAT; i.e., Garmin vivosmart® 4). Garmin wearable PA trackers are widely used across health research, and will be provided to all participants to objectively track PA habits throughout the intervention.

4. Qualitative Interviews and Photo Elicitation: Qualitative data will be gathered across the co-creation process via interviews and photo elicitation, to inform the feasibility of ACE-Neuro, as well as to assess outcomes associated with participation in the ACE-Neuro program (benefits, barriers, satisfaction, impact on well-being). Qualitative data will be stored on a secure server.

HEALTH COACHING

In addition to exercise delivery and assessments, all participants will have the choice to participate in evidence-based health coaching calls, provided by a trained Health Coach. Health coaching is an evidence-based tool that supports positive health behaviour change across cancer populations. Health coaching calls will take place weekly for 15-30 minutes following an individualized exercise training session, and include topics surrounding goal setting, social support, stress management, maintaining motivation, and overcoming barriers. Health coaching calls will be delivered remotely (e.g., via end-to-end encrypted Zoom or phone call) at the participants' preferred date and time.

TIMELINE

The described exercise program and data collection of PROs and functional fitness assessments are in addition to standard practices. The timeline for these assessments include: baseline (at recruitment into ACE-Neuro), 12-weeks (post-intervention), 6-months, and 12-months.

ANALYSIS Quantitative analysis will include descriptive statistics (means, medians, standard deviations), and change scores to measure changes in outcomes over time. Qualitative data will be analyzed by verbatim transcription (in NVivo), using an interpretive description methodology. Both quantitative and qualitative data will be analyzed to provide a deeper understanding of the feasibility and impact of ACE-Neuro.

RELEVANCE By working directly with patients, healthcare providers, and community partners, this implementation project will develop a framework that streamlines patient triage, and provides a tailored online exercise program for neuro-oncology patients, thereby advancing exercise oncology research and clinical practice.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 70
• Est. completion date: April 15, 2024
• Est. primary completion date: December 2, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• are a neuro-oncology patient with primary brain tumour (malignant or benign)

• are pre-, on, or completed treatment

• are over the age of 18 years

• are able to read/write in English

• are able to participate in mild levels of exercise

• are able to access remote programming (i.e., has internet access and a computer or tablet)

Exclusion Criteria:

• diagnosis is not primary brain

• unable to read/write in English

• are unable to participate in light exercise

• for online programs, do not have internet or computer access

Related Conditions & MeSH terms

• Brain Neoplasms
• Brain Tumor, Primary
• Cancer
• Neoplasms

Intervention

Behavioral:
• Tailored Exercise Intervention
The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.

Locations

Country	Name	City	State
Canada	Health and Wellness Lab, University of Calgary	Calgary	Alberta
Canada	Tom Baker Cancer Centre	Calgary	Alberta
Canada	Cancer Rehabilitation Clinic, Faculty of Rehabilitation Medicine, University of Alberta	Edmonton	Alberta
Canada	Cross Cancer Institute, University of Alberta	Edmonton	Alberta

Sponsors (5)

Lead Sponsor	Collaborator
University of Calgary	Alberta Cancer Foundation, Cross Cancer Institute, Tom Baker Cancer Centre, University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of Referral: Referral Rate	The percentage of patient referrals to the study team from the clinical team from patients eligible.	From start of study recruitment to end of study (2 years).
Primary	Feasibility of Enrolment: Enrolment Rate	The percentage of patients that enrol in the study once they hear the full study introduction.	From start of study recruitment to end of study (2 years).
Primary	Feasibility of Triage: Triage Completion Rate	The percentage of participants that attend, from those that are referred, to the Neuro-Oncology Rehabilitation Triage Clinic.	From start of study recruitment to end of study (2 years).
Primary	Feasibility of Program Attendance: Program Attendance Rate	Percentage of classes attended by enrolled participants.	Baseline to 12 weeks.
Primary	Feasibility of Measurement Completion: Measurement Completion Rate (Baseline)	Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.	At baseline (0 weeks).
Primary	Feasibility of Measurement Completion: Measurement Completion Rate (12 Weeks)	Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.	Post-program completion (12 weeks).
Primary	Feasibility of Measurement Completion: Measurement Completion Rate (6 Months)	Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.	At 6 months post study enrolment.
Primary	Feasibility of Measurement Completion: Measurement Completion Rate (12 Months)	Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.	At 12 months post study enrolment.
Primary	Safety of Intervention	Record of any adverse events related to the intervention.	Baseline to 12 weeks.
Primary	Attrition Rate	Number of participants who consent but do not complete the intervention.	Baseline to 12 weeks.
Primary	Qualitative Feasibility: Qualitative Semi-Structured One-on-One Interviews	Participant perception of intervention feasibility via semi-structured one-on-one interviews (qualitative data, not reported on a scale).	Conducted between weeks 12-14.
Secondary	Physical Activity Minutes Per Week	Change in number of participants meeting Guidelines for Physical Activity of 90 minutes per week of moderate intensity exercise, based on accelerometer data from commercially-available activity tracker (Garmin vivosmart® 4).	Baseline to 12 weeks.
Secondary	Weekly Step Count	Total weekly step count based on data from commercially-available activity tracker (Garmin vivosmart® 4).	Baseline to 12 weeks.
Secondary	Body Composition	Measure of change in body mass index (BMI) over time.	Baseline to post 12-week exercise intervention.
Secondary	Cardiorespiratory Fitness	Change in 6-minute walk test (m) or 2-minute step test (steps) results.	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Muscular Strength	Change in hand-grip dynamometry (kg).	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Muscular Endurance	Change in sit-to-stand (number of repetitions in 30 seconds).	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Upper Extremity Flexibility	Change in active shoulder flexion range of motion (degrees).	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Lower Extremity Flexibility	Change in sit-and-reach test (cm).	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Static Balance	Change in one single-leg-stance test (seconds).	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Symptom Burden	Change in Edmonton Symptom Assessment Scale. Scale includes 10 questions total and is from 0-10, where 0 means the symptom is absent and 10 means the worst possible severity of the symptom is being experienced. Total score 0-100, higher is worse.	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Subjective Reporting of Average Weekly Physical Activity	Change in Godin Leisure Time Exercise Questionnaire (GLTEQ). Self-reported as total minutes of physical activity in the past week. Calculated as [mild frequency per week x 3] + [moderate frequency per week x 5] + [strenuous frequency per week x 9]. Minimum score is 0, the maximum is dependent on the participant's frequency of physical activity. Higher score indicates more physical activity.	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Fatigue	Change in Functional Assessment of Chronic Illness Therapy - Fatigue subscale Scale is from 0-4, where 0 means "not at all" and 4 means "very much". Total score 0-52, higher score is lower fatigue severity.	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Quality of Life - Brain Subscale	Change in Functional Assessment of Cancer Therapy - Brain Subscale. Scale is from 0-4, where 0 means "not at all" and 4 means "very much". Total score ranges from 0-200. A higher score indicates a better outcome.	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Cognition	Change in Functional Assessment of Cancer Therapy - Cognitive Subscale. Scale is from 0-4, where 0 means "never" and 4 means "several times a day" (experiencing symptoms). Total score ranges from 0-80. A higher score indicates a better outcome.	Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.
Secondary	Program Implementation and Evaluation	The RE-AIM Framework: program reach, effectiveness, adoption, implementation and maintenance.	Baseline to 2 years.